Release of experimental retinal vein occlusions by direct intraluminal injection of ocriplasmin

Purpose Retinal vein occlusions (RVO) are a major cause of vision loss in people aged 50 years and older. Current therapeutic options limit the consequences of RVO but do not eliminate the cause. Cannulation of the involved vessel and removal of the clot may provide a more permanent solution with a less demanding follow-up. However, cannulation of smaller retinal veins remains challenging. This paper explores the use of ocriplasmin (recombinant plasmin without its kringles) to clear RVO, using a robotic micromanipulator. Methods Branch RVO were induced in a porcine model with rose bengal followed by 532 nm endolaser to the superior venous branch of the optic nerve. The vein was cannulated proximal to the occlusion or beyond the first branching vessel from the obstruction. The vein was infused with a physiologic citric acid buffer solution (CAM) or CAM/ocriplasmin. The time of cannulation, number of attempts, and the ability to release the thrombus were recorded. Results Cannulation and infusion was possible in all the cases. The use of a micromanipulator allowed for a consistent cannulation of the retinal vein and positional stability allowed the vein to remain cannulated for up to 20 min. In none of the attempts (5/5) with CAM did the thrombus dissolve, despite repeat infusion/relaxation cycles. In 7/7 injections of CAM/ocriplasmin near to the point of obstruction, the clot started to dissolve within a few minutes of injection. An infusion, attempted beyond the first venous branch point proximal to the clot, was unsuccessful in 2/3 attempts. Conclusions Ocriplasmin is effective in resolving RVO if injected close to the site of occlusion with the use of a micromanipulator.

[1]  W. Green,et al.  BRANCH RETINAL VEIN OCCLUSION: A Clinicopathologic Case Report , 1987, Retina.

[2]  Marc D de Smet,et al.  Robotic Assisted Cannulation of Occluded Retinal Veins , 2016, PloS one.

[3]  T. Starzl,et al.  Synthesis of human plasminogen by the liver. , 1980, Science.

[4]  A. Rezac Branch , 2018, Encyclopedia of Database Systems.

[5]  W R Green,et al.  Histopathologic study of nine branch retinal vein occlusions. , 1982, Archives of ophthalmology.

[6]  M. Vanhove,et al.  Characterization of a Stabilized Form of Microplasmin for the Induction of Posterior Vitreous Detachment , 2010, Current eye research.

[7]  L. Bynoe,et al.  RETINAL ENDOVASCULAR SURGERY FOR CENTRAL RETINAL VEIN OCCLUSION: Initial Experience of Four Surgeons , 2004, Retina.

[8]  I. Iandiev,et al.  Effects of arteriolar constriction on retinal gene expression and Müller cell responses in a rat model of branch retinal vein occlusion , 2014, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  Bernd Junker,et al.  Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study. , 2007, Ophthalmology.

[10]  Tien Yin Wong,et al.  The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. , 2010, Ophthalmology.

[11]  N. Nagai,et al.  Comparative effects of microplasmin and tissue‐type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice , 2004, Journal of thrombosis and haemostasis : JTH.

[12]  G. Hutchins,et al.  CENTRAL RETINAL VEIN OCCLUSION: A Prospective Histopathologic Study of 29 Eyes in 28 Cases , 2005, Retina.

[13]  Yasushi Ikuno,et al.  COMPARISON OF SURGICAL TREATMENTS FOR CENTRAL RETINAL VEIN OCCLUSION; RON VS. CANNULATION OF TISSUE PLASMINOGEN ACTIVATOR INTO THE RETINAL VEIN , 2009, Retina.

[14]  P. Wiedemann,et al.  Retinal vein thrombosis: pathogenesis and management , 2010, Journal of thrombosis and haemostasis : JTH.

[15]  D. Collen,et al.  Mechanisms of physiological fibrinolysis. , 1995, Bailliere's clinical haematology.

[16]  B. Willekens,et al.  Microplasmin: ex vivo characterization of its activity in porcine vitreous. , 2009, Investigative ophthalmology & visual science.

[17]  N. Berker,et al.  Surgical treatment of central retinal vein occlusion , 2008, Acta ophthalmologica.

[18]  David J. Wilson,et al.  Natural History and Histology in a Rat Model of Laser-Induced Photothrombotic Retinal Vein Occlusion , 2008, Current eye research.

[19]  H. Wildiers,et al.  Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? , 2014, Journal of geriatric oncology.

[20]  J. Garcia-Arumi,et al.  MANAGEMENT OF MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION WITH SHEATHOTOMY AND RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR , 2004, Retina.

[21]  N. Nagai,et al.  Recombinant human microplasmin: production and potential therapeutic properties , 2003, Journal of thrombosis and haemostasis : JTH.

[22]  J. Schaller,et al.  The plasmin–antiplasmin system: structural and functional aspects , 2011, Cellular and Molecular Life Sciences.

[23]  D. Gorog,et al.  Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk. , 2015, Journal of the American College of Cardiology.

[24]  C. Pournaras,et al.  Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[25]  Matus Rehak,et al.  Branch Retinal Vein Occlusion: Pathogenesis, Visual Prognosis, and Treatment Modalities , 2008, Current eye research.

[26]  Mark S. Humayun,et al.  Natural course of experimental retinal vein occlusion in rabbit; arterial occlusion following venous photothrombosis , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.